Abbott Diagnostics Looking Beyond FDA Consent Decree In 2002

Abbott Labs is forecasting diagnostics sales growth in the "mid to high single-digit" range in 2002, with the final resolution of its consent decree with FDA and a series of planned product launches, including Prism high-throughput automated blood screening system assays